JLHL Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹353 Cr
verified against source
Revenue YoY
20.5%
reported change
EBITDA
₹78.1 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jupiter Life Line Hospitals reported steady Q1 FY26 results with total income of 347.6 crore (up 20.5% YoY) and EBITDA of 78.1 crore (up 19.6% YoY) maintaining a 22.5% margin. PAT margin compressed to 12.6% due to 10+ crore increase in depreciation from last year's 100 new census beds, OT upgrades, and surgical robotics/MRI/Cath lab additions, alongside higher finance costs from new debt. Patient volumes grew 11.7% to ~2.6 lakh, while occupancy diluted to 60.1% (from 63.9%) on expanded bed capacity, though absolute occupancy is ~5% higher. Pune and Indore drove volume growth as Thane operates near maturity at mid-70s occupancy. Three greenfield projects (Dombivli, Pune Phase 2, Mira Road) remain on track with Dombivli expected to contribute from FY27. Net cash position of 275 crore provides funding headroom. PAT margins will face compression through FY26 as depreciation and finance costs are elevated. Dombivli will be EBITDA-negative in Year 1 with ~2-2.5 month ramp-up to break-even. Solar plant addition (1.2 MW in MP, total 6.88 MW renewable) will generate ~1 crore annual savings.
Colored figures show movement against the previous available record.
Guidance to track
- While EBITDA margins will hold around current levels, the gap between EBITDA and PAT will widen through FY26 due to ~10 crore quarterly incremental depreciation and higher finance costs from last year's capex cycle.
- Currently halfway through capex with ~200 crore already incurred; ~200 crore more to be spent. Hospital expected to achieve EBITDA break-even by Year 2 with ramp-up of 2-2.5 months to break-even as experienced in past greenfield projects.
- Following the 15-25-60% thumb rule for project implementation over 3 years, Pune's next-phase spending will be approximately 15% of total project cost in FY27, with bulk of capex already behind.
- Management expects nationwide insurance penetration growth to reflect in patient mix at all three hospitals, sustaining the trajectory from current 56.3% insurance share.
Risks flagged
- Environmental permissions for Thane's additional floor are stalled due to ongoing Supreme Court proceedings affecting all new environmental clearances in the area. No timeline available for resolution.
- While Year 2 EBITDA break-even is guided, management admitted they are not 'astrologers' and cannot precisely forecast ramp-up speed. Competitive landscape from upcoming Pune hospital could impact market capture.
- Government schemes represent only 1.4% of revenue currently, but regulatory changes or reimbursement rate cuts in state insurance schemes could disproportionately impact Indore which relies on this segment.
- Arose from noting that ~10%+ ARPOB growth exceeds inflation, attributed to case mix. Analyst questioned sustainability if complex procedures don't materialize as expected, especially at Pune which management acknowledged has limited further case mix upside.
Key quotes
- The gap between PAT and EBITDA is expected to widen leading to lower PAT margins this year. The capex incurred in the last year including the 100 new census beds, the new OTs, biomedical enhancements that is the surgical robots, MRIs, cath labs, etc. have increased the depreciation load by over 10 crores this quarter compared to the same period last year.
- First year Dombivli should have negative EBITDA to some number. While on the individual strength, the three hospitals will continue performing in line as they should, but on a consolidated level next year there should be some compression on account of Dombivli.
- All the hospitals we expect the peak to be in the mid-70% range. In absolute terms, the occupancy is higher by about 5% compared to last year.
Research modules